{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:45:45Z","timestamp":1789371945062,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,6,26]],"date-time":"2013-06-26T00:00:00Z","timestamp":1372204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1245\/s10434-013-3077-4","type":"journal-article","created":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T18:38:40Z","timestamp":1372185520000},"page":"3892-3898","source":"Crossref","is-referenced-by-count":20,"title":["Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study"],"prefix":"10.1245","volume":"20","author":[{"given":"J.","family":"Hommell-Fontaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Passot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Decullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Traverse-Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. N.","family":"Gilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,26]]},"reference":[{"key":"3077_CR1","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1046\/j.1365-2168.2000.01571.x","volume":"87","author":"G Sebbag","year":"2000","unstructured":"Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87:1587-93.","journal-title":"Br J Surg."},{"key":"3077_CR2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/annonc\/mdl428","volume":"18","author":"TD Yan","year":"2007","unstructured":"Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827-34.","journal-title":"Ann Oncol."},{"key":"3077_CR3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/030089160308900307","volume":"89","author":"YI Acherman","year":"2003","unstructured":"Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89:269-73.","journal-title":"Tumori."},{"key":"3077_CR4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1245\/s10434-009-0756-2","volume":"17","author":"D Baratti","year":"2010","unstructured":"Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17:45-53.","journal-title":"Ann Surg Oncol."},{"key":"3077_CR5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1245\/ASO.2006.05.041","volume":"13","author":"C Brigand","year":"2006","unstructured":"Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13:405-12.","journal-title":"Ann Surg Oncol."},{"key":"3077_CR6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1245\/ASO.2006.03.045","volume":"13","author":"M Deraco","year":"2006","unstructured":"Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229-37.","journal-title":"Ann Surg Oncol."},{"key":"3077_CR7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0399-8320(07)73964-7","volume":"31","author":"D Elias","year":"2007","unstructured":"Elias D, Bedard V, Bouzid T, Duvillard P, Kohneh-Sharhi N, Raynard B, Goere D. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007;31:784-8.","journal-title":"Gastroenterol Clin Biol."},{"key":"3077_CR8","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","volume":"21","author":"AL Feldman","year":"2003","unstructured":"Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560-7.","journal-title":"J Clin Oncol."},{"key":"3077_CR9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COC.0b013e3180684181","volume":"31","author":"ME Hesdorffer","year":"2008","unstructured":"Hesdorffer ME, Chabot JA, Keohan ML, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31:49-54.","journal-title":"Am J Clin Oncol."},{"key":"3077_CR10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ejso.2010.07.001","volume":"36","author":"MD Kluger","year":"2010","unstructured":"Kluger MD, Taub RN, Hesdorffer M, Jin Z, Chabot JA. Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: operative morbidity and mortality in phase I and II trials. Eur J Surg Oncol. 2010;36:997-1003.","journal-title":"Eur J Surg Oncol."},{"key":"3077_CR11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0021-7697(08)74654-4","volume":"145","author":"G Passot","year":"2008","unstructured":"Passot G, Cotte E, Brigand C, Beaujard AC, Isaac S, Gilly FN, Glehen O. Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. J Chir. 2008;145:447-53.","journal-title":"J Chir."},{"key":"3077_CR12","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605-21.","DOI":"10.1016\/S1055-3207(03)00045-0"},{"key":"3077_CR13","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/bjs.5377","volume":"93","author":"TD Yan","year":"2006","unstructured":"Yan TD, Popa E, Brun EA, Cerruto CA, Sugarbaker PH. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg. 2006;93:1536-42.","journal-title":"Br J Surg."},{"key":"3077_CR14","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ejso.2006.05.009","volume":"32","author":"TD Yan","year":"2006","unstructured":"Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:948-53.","journal-title":"Eur J Surg Oncol."},{"key":"3077_CR15","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1245\/s10434-010-1080-6","volume":"17","author":"AU Blackham","year":"2010","unstructured":"Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17:2720-7.","journal-title":"Ann Surg Oncol."},{"key":"3077_CR16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jso.21177","volume":"99","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99:109-13.","journal-title":"J Surg Oncol."},{"key":"3077_CR17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12253-009-9210-9","volume":"16","author":"TC Chua","year":"2010","unstructured":"Chua TC, Yao P, Akther J, Morris DL. Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy. Pathol Oncol Res. 2010;16:217-22.","journal-title":"Pathol Oncol Res."},{"key":"3077_CR18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/000313480106701019","volume":"67","author":"BW Loggie","year":"2001","unstructured":"Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67:999-1003.","journal-title":"Am Surg."},{"key":"3077_CR19","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237-42.","journal-title":"J Clin Oncol."},{"key":"3077_CR20","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.25640","volume":"117","author":"TD Yan","year":"2011","unstructured":"Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117:1855-63.","journal-title":"Cancer."},{"key":"3077_CR21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1245\/s10434-006-9187-5","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: a prospective study of 70 consecutive cases. Ann Surg Oncol. 2007;14:515-25.","journal-title":"Ann Surg Oncol."},{"key":"3077_CR22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1245\/s10434-008-0219-1","volume":"16","author":"D Baratti","year":"2009","unstructured":"Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Diffuse malignant peritoneal mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2009;16:463-72.","journal-title":"Ann Surg Oncol."},{"key":"3077_CR23","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1158\/1078-0432.CCR-04-1884","volume":"11","author":"AC Borczuk","year":"2005","unstructured":"Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11:3303-8.","journal-title":"Clin Cancer Res."},{"key":"3077_CR24","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.5858\/2006-130-1654-PSOHPI","volume":"130","author":"CA Cerruto","year":"2006","unstructured":"Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130:1654-61.","journal-title":"Arch Pathol Lab Med."},{"key":"3077_CR25","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1002\/cncr.21239","volume":"104","author":"D Nonaka","year":"2005","unstructured":"Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005;104:2181-8.","journal-title":"Cancer."},{"key":"3077_CR26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/modpathol.2009.186","volume":"23","author":"AM Krasinskas","year":"2010","unstructured":"Krasinskas AM, Bartlett DL, Cieply K, Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol. 2010;23:531-8.","journal-title":"Mod Pathol."},{"key":"3077_CR27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1245\/s10434-006-9169-7","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41-9.","journal-title":"Ann Surg Oncol."},{"key":"3077_CR28","doi-asserted-by":"crossref","first-page":"334A","DOI":"10.1038\/sj.modpathol.3801046","volume":"21","author":"A Acurio","year":"2008","unstructured":"Acurio A, Arif Q, Gattuso P, McIntere M, Krausz T, Husain AN. Value of immunohistochemical markers in differentiating benign from malignant mesothelial lesion. Mod Pathol. 2008;21:334A.","journal-title":"Mod Pathol."},{"key":"3077_CR29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/modpathol.3800732","volume":"20","author":"Y Kato","year":"2007","unstructured":"Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20:215-20.","journal-title":"Mod Pathol."},{"key":"3077_CR30","doi-asserted-by":"crossref","first-page":"804","DOI":"10.5858\/arpa.2011-0219-OA","volume":"136","author":"SM Lagana","year":"2012","unstructured":"Lagana SM, Taub RN, Borczuk AC. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions. Arch Pathol Lab Med 2012;136:804-9.","journal-title":"Arch Pathol Lab Med"},{"key":"3077_CR31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1309\/AJCPP5R2ZJZKCLWN","volume":"135","author":"SE Monaco","year":"2011","unstructured":"Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135:619-27.","journal-title":"Am J Clin Pathol."},{"key":"3077_CR32","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T","volume":"92","author":"G Cantuaria","year":"2001","unstructured":"Cantuaria G, Fagotti A, Ferrandina G, et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001;92:1144-50.","journal-title":"Cancer."},{"key":"3077_CR33","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1677\/ERC-08-0211","volume":"16","author":"W Fenske","year":"2009","unstructured":"Fenske W, Volker HU, Adam P, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer. 2009;16:919-28.","journal-title":"Endocr Relat Cancer."},{"key":"3077_CR34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E","volume":"83","author":"RS Haber","year":"1998","unstructured":"Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34-40.","journal-title":"Cancer."},{"key":"3077_CR35","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1097-0142(20010801)92:3<634::AID-CNCR1364>3.0.CO;2-X","volume":"92","author":"T Kawamura","year":"2001","unstructured":"Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634-41.","journal-title":"Cancer."},{"key":"3077_CR36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12253-010-9281-7","volume":"17","author":"M Legan","year":"2011","unstructured":"Legan M, Tevzic S, Tolar A, Luzar B, Marolt VF. Glucose transporter-1 (GLUT-1) immunoreactivity in benign, premalignant and malignant lesions of the gallbladder. Pathol Oncol Res. 2011;17:61-6.","journal-title":"Pathol Oncol Res."},{"key":"3077_CR37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.oraloncology.2006.06.006","volume":"43","author":"Y Mori","year":"2007","unstructured":"Mori Y, Tsukinoki K, Yasuda M, Miyazawa M, Kaneko A, Watanabe Y. Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors. Oral Oncol. 2007;43:563-9.","journal-title":"Oral Oncol."},{"key":"3077_CR38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/modpathol.2009.6","volume":"22","author":"IH Ozbudak","year":"2009","unstructured":"Ozbudak IH, Shilo K, Tavora F, et al. Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. Mod Pathol. 2009;22:633-8.","journal-title":"Mod Pathol."},{"key":"3077_CR39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.prp.2009.07.018","volume":"206","author":"JY Sung","year":"2010","unstructured":"Sung JY, Kim GY, Lim SJ, Park YK, Kim YW. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol Res Pract. 2010;206:24-9.","journal-title":"Pathol Res Pract."},{"key":"3077_CR40","first-page":"1923","volume":"6","author":"SC Kao","year":"2012","unstructured":"Kao SC, Klebe S, Henderson DW, et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol. 2012;6:1923-9.","journal-title":"J Thorac Oncol."},{"key":"3077_CR41","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.humpath.2006.12.013","volume":"38","author":"L Kleinberg","year":"2007","unstructured":"Kleinberg L, Lie AK, Florenes VA, Nesland JM, Davidson B. Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol. 2007;38:986-94.","journal-title":"Hum Pathol."},{"key":"3077_CR42","first-page":"453","volume":"29","author":"N Zaffaroni","year":"2007","unstructured":"Zaffaroni N, Costa A, Pennati M, et al. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol. 2007;29:453-66.","journal-title":"Cell Oncol."},{"key":"3077_CR43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29-42.","journal-title":"Ann Surg."},{"key":"3077_CR44","first-page":"124","volume":"41","author":"FN Gilly","year":"1994","unstructured":"Gilly FN, Carry PY, Sayag AC, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41:124-9.","journal-title":"Hepatogastroenterology."},{"key":"3077_CR45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-74.","journal-title":"Cancer Treat Res."},{"key":"3077_CR46","volume-title":"World Health Organization Classification of Tumors: pathology and genetics of tumors of the Lung, Pleura, Thymus and Heart","author":"WD Travis","year":"2004","unstructured":"Travis WD, Brambilla E, M\u00fcller-Hermelink HK, Harris CC. World Health Organization Classification of Tumors: pathology and genetics of tumors of the lung, pleura, thymus and heart. 3rd ed. Lyon: IARC Press; 2004.","edition":"3"},{"key":"3077_CR47","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","volume":"29","author":"Y Benjamini","year":"2001","unstructured":"Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29:1165-88.","journal-title":"Ann Statist."},{"key":"3077_CR48","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(85)90526-4","volume":"2","author":"KH Antman","year":"1985","unstructured":"Antman KH, Osteen RT, Klegar KL, Amato DA, Pomfret EA, Larson DA, Corson JM. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2:977-81.","journal-title":"Lancet."},{"key":"3077_CR49","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/cncr.10209","volume":"94","author":"SA Kerrigan","year":"2002","unstructured":"Kerrigan SA, Turnnir RT, Clement PB, Young RH, Churg A. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer. 2002;94:378-85.","journal-title":"Cancer."},{"key":"3077_CR50","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/jcp.20166","volume":"202","author":"ML Macheda","year":"2005","unstructured":"Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654-62.","journal-title":"J Cell Physiol."},{"key":"3077_CR51","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.ejca.2012.01.016","volume":"48","author":"K Kaira","year":"2012","unstructured":"Kaira K, Serizawa M, Koh Y, et al. Relationship between (18)F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012;48:1244-54.","journal-title":"Eur J Cancer."}],"updated-by":[{"DOI":"10.1245\/s10434-013-3389-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T00:00:00Z","timestamp":1388793600000}}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-3077-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-013-3077-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-3077-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T16:06:26Z","timestamp":1688313986000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-013-3077-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,26]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["3077"],"URL":"https:\/\/doi.org\/10.1245\/s10434-013-3077-4","relation":{"correction":[{"id-type":"doi","id":"10.1245\/s10434-013-3389-4","asserted-by":"object"}]},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,26]]}}}